Emily Walsh is a “recovering scientist" and life sciences professional with expertise managing drug discovery and clinical programs across a breadth of indications in biotech and pharma. Prior to joining Halloran Consulting Group in 2011, Emily founded Tremont Therapeutics, a small virtual biotech focused on identifying and developing promising therapeutics from academia from mid-discovery through human proof of concept.
Emily has also held a number of roles including management and leadership responsibilities in the Novartis Drug Discovery Incubator at the Novartis Institutes for Biomedical Research. This group sought to internally “partner” high-risk discovery programs within Novartis for full clinical development. Subsequently, Emily was responsible for business, financial, alliance and scientific program management across a number of research and development programs at Alnylam Pharmaceuticals including the respiratory syncytial virus therapeutics program.
Emily was selected one of the Boston Business Journal’s “40 under 40” honorees in 2009. Emily earned her Ph.D. from University of California, San Francisco, and performed her postdoctoral work with Eric Lander at the Broad Institute.